Six month report January-June 2000

Six month report January - June 2000: Continued good growth * Total revenues up 12% to SEK 10,514 M, with a 13% increase in EBITDA to SEK 2,059 M, a 9% growth in earnings per share to SEK 0.72 and a 14% increase in cash earnings per share to SEK 3.98. Earnings per share including non-recurring items increased by 53% to SEK 3.59. * Continued strong expansion (+18%) in the clinics operations, Gambro Healthcare. * Good sales growth of 6% for Gambro Renal Products with a strong second quarter. * Good progress for blood component technology, Gambro BCT. Revenues up 12% and further progress in Pathogen Eradication Technology. * Satisfactory solution of the US laboratory billings issue. * Positive tax ruling - provision of SEK 903 M reversed. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, +46-8-613 65 00,+46-70-513 65 33 Lars Granlöf, Senior Vice President, CFO, +46-8-613 65 00 Anna Augustson, European Investor Relations Manager, +46-8-613 65 35, +46-70-513 65 34 Cindy Lyman or Kerry Schneider, Citigate Dewe Rogerson, New York , tel.+1-212-688 6840 Gambro's financial information is also available on the Internet: www.gambro.com ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/07/26/20000726BIT00020/bit0001.doc http://www.bit.se/bitonline/2000/07/26/20000726BIT00020/bit0002.pdf